Combination of pegilodecakin and docetaxel shows synergy in tumor rejection in immune resistant TNBC model

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 29; p. viii421
Main Authors Ratti, N., Shifrin, N., McCauley, S., Verma, R., Van Vlasselaer, P., Oft, M., Leveque, J.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.10.2018
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdy288.053